PetMed Express, Inc. (PETS)

Several events have impacted PetMed Express, Inc.'s stock price in the past six months. The company's Q2 2026 earnings reported an EPS of -$0.41, missing analysts' estimates. Cardone Ventures, LLC proposed to acquire PetMed Express, Inc. for $89.3 million, and SilverCape Investments made a takeover offer of $4 per share. James LaCamp was appointed to the Board of Directors and as Chair of the Audit Committee. The company filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, reporting a net loss of $6.3 million. A delay in filing the 10-K was due to an investigation by the Audit Committee. The company's share price declined by 30.40% between January 10, 2025, and January 9, 2026, and the stock has experienced high volatility.

While specific details on demand seasonality are not explicitly provided, there are indications of seasonal influences. Higher seasonal discounts contributed to a year-over-year decline in revenue for the third fiscal quarter ended December 31, 2024, suggesting seasonal fluctuations in sales, potentially around holiday periods. The nature of pet medication and supply sales might also imply some seasonality related to factors like flea and tick season or holiday gift-giving.

PetMed Express, Inc., also known as PetMeds, is a direct-to-consumer pet pharmacy located in Delray Beach, Florida, operating in the retail trade sector, specifically drug retailers or specialty retail. It focuses on consumer discretionary and consumer cyclicals, marketing and selling prescription and non-prescription pet medications, health products, food, supplements, and pet supplies for dogs, cats, and horses. The company offers over 15,000 SKUs, including preventatives, medications, and pet supplies, sold through its websites, mobile app, toll-free numbers, customer support center, and employer benefit partnerships.

PetMed Express, Inc. primarily serves customers in the United States and is licensed as a pet pharmacy in all 50 states. The company's headquarters and distribution facility are located in Delray Beach, Florida.

PetMed Express has a strong reputation as a trusted national online pharmacy for pet healthcare. However, its reputation has been subject to scrutiny due to an investigation by its Audit Committee, which led to a delay in filing the company's annual report. The investigation concerned anonymous reports regarding revenue recognition for autoship orders, customer complaints, and a coupon promotion. The ongoing investigation could affect public perception.

PetMed Express, Inc. has a mix of institutional, retail, and individual investors. 122 institutional owners and shareholders hold a total of 8,154,004 shares. Major institutional owners include Renaissance Technologies Llc, Vanguard Group Inc, Hotchkis & Wiley Capital Management Llc, BlackRock, Inc., Federated Hermes, Inc., Dimensional Fund Advisors Lp, and Oaktop Capital Management Ii, L.p. Institutional investors own approximately 20.71% to 26.64% of the company's stock, while insiders own around 28.99%, and public companies and individual investors hold approximately 5.93% to 44.37%.